Related Experiment Video
Updated: Aug 17, 2025

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
Incidence and associated risk factors for systemic drug levels with inhaled aminoglycoside therapy
Jennifer M Schultheis1, Mary E Durham2, Shawn J Kram1
1Department of Pharmacy, Duke University Hospital, Durham, NC, USA.
Objectives:
To characterize the incidence of and risk factors for a detectable drug level (DDL) in patients that received inhaled aminoglycoside therapy.
Methods:
This retrospective, single-centre study included adult patients who received at least one dose of an inhaled aminoglycoside with a drug level during inpatient hospitalization. Patients were excluded if they received an aminoglycoside intravenously within 7 days or if the drug level was not drawn within 4 h of the next dose. A repeated measures logistic regression model evaluated the association between potential risk factors and a DDL.
Results:
Among 286 drug levels, 88 (30.8%) drug levels were detectable. In multivariable analysis, cystic fibrosis (CF) (OR: 3.03; 95% CI: 1.10-8.35), chronic kidney disease (CKD) (OR: 4.25; 95% CI: 1.84-9.83), lung transplant recipient (OR: 3.08; 95% CI: 1.09-8.73), mechanical ventilation (OR: 2.99; 95% CI: 1.25-7.15) and tobramycin (OR: 5.26; 95% CI: 2.35-11.78) were associated with higher odds of a DDL. Among those with a DDL, inhaled aminoglycoside type and drug level concentration were not associated with acute kidney injury (P = 0.161).
Conclusions:
Among 286 drug levels identified among inpatients receiving inhaled aminoglycoside therapy, 88 (30.8%) unique drug levels were detectable. Based on the results of this study, periodic trough concentrations should be considered for patients receiving inhaled aminoglycoside therapy with CF, CKD, lung transplantation, mechanical ventilation or tobramycin.
Insights
Detecting inhaled aminoglycoside levels is crucial. Patients with cystic fibrosis, chronic kidney disease, lung transplants, or on mechanical ventilation have higher risks of detectable drug levels.
Area of Science:
- Pharmacology and Therapeutics
- Pulmonary Medicine
- Nephrology
Background:
- Inhaled aminoglycosides are vital for treating respiratory infections.
- Monitoring drug levels is essential for optimizing therapy and minimizing toxicity.
- Risk factors for detectable drug levels (DDLs) in this population require characterization.
Purpose of the Study:
- To determine the incidence of DDLs in patients receiving inhaled aminoglycoside therapy.
- To identify risk factors associated with achieving DDLs in this patient group.
Main Methods:
- Retrospective, single-center study of adult inpatients receiving inhaled aminoglycosides.
- Drug levels were analyzed, excluding those with recent IV aminoglycoside use or improper timing.
- Logistic regression modeled associations between risk factors and DDLs.
Main Results:
- 30.8% of 286 drug levels were detectable.
- Cystic fibrosis (CF), chronic kidney disease (CKD), lung transplant, mechanical ventilation, and tobramycin use were linked to higher DDL odds.
- No association found between DDLs and acute kidney injury.
Conclusions:
- A significant proportion of inhaled aminoglycoside doses result in detectable drug levels.
- Consider monitoring trough concentrations in patients with CF, CKD, lung transplant, mechanical ventilation, or on tobramycin.
More Related Videos
07:10Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung
Published on: May 20, 2019
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Additional Routes of Drug Administration
Administering drugs via inhalation allows for the direct delivery of gaseous, volatile substances or droplets to different parts of the respiratory tract. One of the advantages of the inhalation route is the rapid absorption of drugs into the circulatory system, which is possible because of the large surface area of...
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Factors Affecting Drug Response: Overview
Inhaled Medications
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...